Farmakoterapijska primena SGLT2 inhibitora
Authors/Creators
Abstract (English)
Introduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose
reabsorption and enhance urinary excretion, offering cardiovascular and renoprotective benefits. The aim: Exploring the pharmacodynamic advantages of SGLT2 inhibitors, expanding their therapeutic indications and assessing variations in pharmacological effects among different representatives. Materials and methods: The purpose of this review is to investigate the pharmacological properties of SGLT2 inhibitors and their impact on clinical recommendations. A literature review was conducted using keywords such as nephroprotective and antihyperglycemic properties. Studies from PubMed published between 2000 and 2023 were analyzed. A total of twenty studies were identified, of which eleven were included in the review. Literature review and discussion: On May 20, 2024, 11 original human studies examining the effects of SGLT2 inhibitors were found. Conclusion: In addition to T2DM, SGLT2 inhibitors improve the quality of life and reduce the risk of complications in patients with heart failure and chronic kidney failure. Differences in pharmacodynamic properties between individual representatives are the reason for the differences between indications and their application.
Abstract (Serbian)
Uvod: Inhibitori SGLT2 postaju ključni u lečenju dijabetesa tipa 2 blokiranjem reapsorpcije glukoze u proksimalnim tubulima, što smanjuje hiperglikemiju i pruža kardiovaskularne i renoprotektivne benefite. Cilj istraživanja: Prikazati farmakodinamske osobine SGLT2 inhibitora koje su dovele do proširenju indikacija za njihovu primenu, kao i razlike farmakoloških karakteristika pojedinačnih predstavnika ove grupe lekova koje su uslovile i razlike u indikacijama za njihovu primenu. Materijal i metode: Svrha ovog pregleda je prikazati farmakodinamska svojstva inhibitora SGLT2 kao i njihov uticaj na kliničke preporuke. Sproveden je pregled literature koristeći ključne reči kao što su nefroprotektivna i antihiperglikemijska svojstva. Analizirani su radovi iz PubMed-a objavljeni od 2000. do 2023. godine. Identifikovano je dvadeset studija, od kojih je jedanaest uključeno u pregled. Pregled literature i diskusija: Na dan 20. maj 2024. godine, pronađeno je 11 originalnih studija na ljudima koje su pratile efekte SGLT2 inhibitora. Zaključak: Pored T2DM, SGLT2 inhibitori poboljšavaju
kvalitet života i smanjuju rizik od komplikacija i kod obolelih od srčane insuficijencije i hronične insuficijencije bubrega. Razlike farmakodinamskih svojstava između
pojedinačnih predstavnika su razlog postojanja razlika među indikacijama ua njihovu primenu.
Files
ZZSPUB-2024 Farmakoterapijska primena SGLT2 inhibitora.pdf
Files
(2.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:3984026b7d0363b11bc5fd57dca37437
|
2.8 MB | Preview Download |